The company is now ready to offer clinical testing anywhere in the world after early case studies conducted in Israel have demonstrated recovery within 48 hours
Medical footprint expansion with deeper medical grade skin contact material science expertise
Effectiveness of Covaxin against the Omicron variant is currently being studied
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology
This round of funding will support Fast&Up and Chicnutrix to expand their domestic presence, enhance manufacturing capabilities and accelerate momentum globally
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies
Subscribe To Our Newsletter & Stay Updated
